Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells

Bone

Volumn 49, Issue 4, 2011, Pages 710-716

  Cornish, Jillian ^a   Bava, Usha ^a   Callon, Karen E ^a   Bai, Jizhong ^a   Naot, Dorit ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alendronate; Caco 2; CHO; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; PAMIDRONIC ACID; RAP1 PROTEIN; RAP1A PROTEIN; THYMIDINE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE TISSUE; CANCER CELL CULTURE; CELL ADHESION; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN CACO 2; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; FEMALE; FETUS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PROTEIN PRENYLATION; RAT;

ANIMALS; BLOTTING, WESTERN; BONE AND BONES; CASPASE 3; CATTLE; CELL ADHESION; CELL COUNT; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DIPHOSPHONATES; HUMANS; OSTEOBLASTS; PRENYLATION; RATS; THYMIDINE; TIME FACTORS;

EID: 80052277712     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.020     Document Type: Article

References (35)

1. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
2. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661.
3. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281-290.
4. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004, 75:451-461.
5. Reszka A.A., Halasy-Nagy J., Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001, 59:193-202.
6. Roelofs A.J., Jauhiainen M., Monkkonen H., Rogers M.J., Monkkonen J., Thompson K. Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009, 144:245-250.
7. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
8. Reid I.R., Bolland M.J., Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 2007, 41:318-320.
9. Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
10. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
11. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
12. Morgan G.J., Davies F.E., Gregory W.M., Cocks K., Bell S.E., Szubert A.J., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
13. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003, 21:3150-3157.
14. Berenson J.R., Rosen L.S., Howell A., Parter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - a double-blind, randomized dose-response study. Cancer 2001, 91:1191-1200.
15. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
16. Cornish J., Callon K.E., Lin C.Q.X., Xiao C.L., Mulvey T.B., Cooper G.J.S., et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol Endocrinol Metab 1999, 277:E779-E783.
17. Suri S., Monkkonen J., Taskinen M., Pesonen J., Blank M.A., Phipps R.J., et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001, 29:336-343.
18. Fedorov S.N., Bode A.M., Stonik V.A., Gorshkova I.A., Schmid P.C., Radchenko O.S., et al. Marine alkaloid polycarpine and its synthetic derivative dimethylpolyearpine induce apoptosis in JB6 cells through p53- and caspase 3-dependent pathways. Pharm Res 2004, 21:2307-2319.
19. Pallet N., Bouvier N., Legendre C., Beaune P., Thervet E., Choukroun G., et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010, 61:71-75.
20. Cremers S., Papapoulos S.E., Gelderblom H., Seynaeve C., den Hartigh J., Vermeij P., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 2005, 20:1543-1547.
21. Scheper M.A., Badros A., Chaisuparat R., Cullen K.J., Meiller T.F. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009, 144:667-676.
22. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
23. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
24. Henry D.H., Costa L., Goldwasser F., Hirsh V., Hungria V., Prausova J., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
25. Stopeck A.T., Lipton A., Body J.J., Steger G.G., T.K., de Boer R.H., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
26. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
27. Aviles A., Nambo M.J., Neri N., Castaneda C., Cleto S., Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24:227-230.
28. Rocken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 2010, 120:1800-1803.
29. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351.
30. Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez-MacGregor M., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
31. Rack B., Juckstock J., Genss E.M., Schoberth A., Schindlbeck C., Strobl B., et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
32. Jarrett S.J., Conaghan P.G., Sloan V.S., Papanastasiou P., Ortmann C.-E., O'Connor P.J., et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006, 54:1410-1414.
33. McQueen F., Lloyd R., Doyle A., Robinson E., Lobo M., Exeter M., et al. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the zoledronic acid in psoriatic arthritis (ZAPA) study. Ann Rheum Dis 2011, 70:1091-1094.
34. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
35. Idris A.I., Rojas J., Greig I.R., van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82:191-201.